Pharmamarketeer

EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits

The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the treatment of multiple sclerosis (MS), do not outweigh its risks, following a review carried out by the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) at the request of the European Commission.

Reageer

Medhc-fases-banner
Advertentie(s)